Fabomotisol is a selective non-benzodiazepine anxiolytic.
Acting on σ1-receptors in brain nerve cells, fabomotisol stabilizes GABA/benzodiazepine receptors and restores their sensitivity to endogenous inhibitory mediators. Fabomotisol also increases the bioenergetic potential of neurons and has a neuroprotective effect: it restores and protects nerve cells.
The action of Fabomotisol is realized mainly by a combination of anxiolytic (anti-anxiety) and mild stimulating (activating) effects. Fabomotisol reduces or eliminates anxiety (anxiety, misgivings, fears), irritability, tension (fearfulness, tearfulness, anxiety, inability to relax, insomnia, fear), depressed mood, somatic manifestations of anxiety (muscular, sensory, cardiovascular, respiratory, gastrointestinal symptoms), autonomic disorders (dry mouth, increased sweating, dizziness), cognitive disorders (decreased concentration, memory impairment), including those occurring in stress disorders (adaptation disorders). The use of the drug is especially indicated for persons with predominantly asthenic personality traits in the form of anxious mistrust, uncertainty, increased impressionability and emotional lability, tendency to emotional stress reactions.
The effect of the drug develops on the 5th-7th day of treatment. The maximum effect is achieved at the end of the 4th week of treatment and persists after the end of treatment for an average of 1-2 weeks.
The drug does not cause muscle weakness, drowsiness and does not have a negative effect on concentration and memory. Its use does not develop addiction, drug dependence and withdrawal syndrome.
Pharmacokinetics
Absorption
Fabomotisol is well and rapidly adsorbed from the gastrointestinal tract after oral administration.
The maximum plasma concentration of fabomotisol (Cmax) was 0.130±0.073 μg/mL, and the time to reach maximum concentration (Tmah) was 0.85±0.13 hours.
Metabolism
Fabomotisole undergoes a first-pass effect through the liver, the main routes of metabolism being hydroxylation by the aromatic ring of the benzimidazole cycle and oxidation by the morpholine moiety.
Distribution
Fabomotisol is intensively distributed in well-vascularized organs, it is characterized by rapid transfer from the central pool (blood plasma) to the peripheral pool (highly vascularized organs and tissues).
Withdrawal
The half-life of fabomotisol during oral administration is 0.82±0.54 hours. Short half-life is due to intensive biotransformation of fabomotisol and rapid distribution from blood plasma to organs and tissues. Fabomotisol is eliminated mainly in the form of metabolites, partially – in unchanged form with urine and feces.
With prolonged use does not cumulate in the body.
How to use and dosage
minus
Take orally after meals.
The optimal single dose is 10 mg, the daily dose is 30 mg, which should be divided into 3 doses per day. The duration of the treatment course is 2-4 weeks.
If necessary, on the recommendation of a doctor, the daily dose of the drug can be increased to 60 mg, and the duration of treatment – up to 3 months.
Children
Use of the drug in children under 18 years of age is contraindicated.







Reviews
There are no reviews yet.